Aptevo TherapeuticsAPVO -3.66%29 Buyback Yield % is -669.87 as of Jun. 30, 2026. GuruFocus rates APVO with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 742 Biotechnology companies, Aptevo Therapeutics ranks worse than 99.19% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Aptevo Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Aptevo Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APVO vs ENVB, ADIL, CNSP: Buyback Yield % Comparison
For the Biotechnology subindustry, Aptevo Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptevo Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Aptevo Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptevo Therapeutics (APVO) has a Buyback Yield % of -669.87 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Aptevo Therapeutics and its competitors. According to the industry distribution chart, Aptevo Therapeutics ranks #736 out of 742 companies in the Biotechnology industry, placing it in the top 99.2%.
Is Aptevo Therapeutics' Buyback Yield % too high?
Aptevo Therapeutics' current Buyback Yield % is -669.87. Based on the distribution chart, Aptevo Therapeutics ranks #736 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aptevo Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aptevo Therapeutics' Buyback Yield % compare to ENVB and ADIL?
According to the Biotechnology industry distribution chart, Aptevo Therapeutics ranks #736 out of 742 companies for Buyback Yield %. This places Aptevo Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Aptevo Therapeutics and its competitors. Aptevo Therapeutics's current Buyback Yield % is -669.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptevo Therapeutics stock overvalued right now?
Aptevo Therapeutics (APVO) has a current Buyback Yield % of -669.87. The current Buyback Yield % is -669.87. Aptevo Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Aptevo Therapeutics (APVO), the current Buyback Yield % is -669.87 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
29GF Score
Get the complete analysis for APVO
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APVO has been successfully added to your 
